Etanercept (Enbrel) Special Investigation (Regulatory Post Marketing Commitment Plan): Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Etanercept (Enbrel) Special Investigation (Regulatory Post Marketing Commitment Plan) (NCT01230177), a registered phase not stated study. The primary outcome is Number of Participants With Treatment Related Adverse Events.

2. Clinical Question

The clinical question is therefore primarily about observed safety following a change in dosing regimen, rather than about a comparative treatment effect. The record also lists physician assessment of clinical effect on rheumatoid arthritis symptoms and change in laboratory values as a secondary outcome. Results for that outcome are not reported in the registry record. The aim described in the record includes investigating safety and efficacy under post-marketing use, but the information available does not establish how efficacy was measured beyond the named secondary outcome. Nor does it establish whether the change in regimen caused any observed event or symptom change. The registry record says the sponsor evaluated whether adverse events were causally related to etanercept; the event definition itself includes unfavorable events regardless of causality.

3. Trial Design

This is a completed post-marketing special investigation of etanercept (Enbrel), listed as a regulatory post-marketing commitment plan. The registry record describes a survey among patients with rheumatoid arthritis who had an inadequate response to prior conventional therapy and changed their etanercept regimen from 10 mg twice a week to 25 mg once a week. The listed intervention is etanercept (genetical recombination), and the described group consists of patients making that regimen change.

Enrollment was 3. The study start is recorded as 2011-05, and primary completion as 2013-04. The status is COMPLETED. These record details describe the study timeline and enrollment; they do not supply the date of final analysis or the length of follow-up for every participant. The primary endpoint timeframe is 12 weeks.

A randomized comparison is not reported in the registry record. Allocation is not stated, and the record cautions that the arms are not a like-for-like control comparison. A separate control group is not described in the study details. Consequently, the design information supports reading the investigation as a small post-marketing assessment of patients undergoing the specified regimen change, not as a controlled estimate of the difference between regimens.

The safety analysis population is defined as participants in whom the etanercept regimen changed from 10 mg twice weekly to 25 mg once weekly for rheumatoid arthritis. The registry record does not report a separate efficacy analysis population or further eligibility details. The listed secondary outcome concerns physician assessment of clinical effect on symptoms and change in laboratory values. Detailed assessment procedures, visit schedules beyond the primary timeframe, and methods for recording the secondary outcome are not reported in the registry record.

The record lists 5 outcome measures and 0 analyses. This describes what is listed in the registry record; it does not establish whether analyses were conducted outside the record. The statistical plan, sample-size justification for the investigation, interim analyses, and a more detailed protocol are not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Analysis population for the primary outcome, as defined in the registry: The safety analysis population consisted of the participants in whom the regimen of etanercept was changed from 10 mg twice weekly to 25 mg once weekly for the treatment of rheumatoid arthritis.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Number of Participants With Treatment Related Adverse Events, measured over 12 weeks.

The primary endpoint is the number of participants with treatment-related adverse events during 12 weeks. It is a count of people who experienced an event, rather than a measure of the total number of events or their severity. Counting affected participants gives a direct description of how many people in the safety population had an event classified as treatment-related during the stated timeframe.

The registry record defines adverse events broadly as unfavorable events, including clinically significant abnormal changes in laboratory test values, arising after etanercept administration regardless of whether they were caused by etanercept. It says the sponsor evaluated the causal relationship between an event and etanercept. Thus, the broad event definition and the treatment-related endpoint are not interchangeable: an event could be recorded under the broad definition without being judged treatment-related.

This kind of endpoint is used in safety assessment because it records whether participants experienced events during treatment exposure. It does not, on its own, establish that treatment caused an event. In general, causal interpretation requires attention to the study design, the comparison available, and how causality was assessed. Here, a comparative control is not reported in the registry record, and the primary endpoint result is not reported in the registry record. The recorded adverse-event figures therefore should not be treated as the missing primary endpoint result.

The primary endpoint is stated in terms of participants, but a numerical count for that outcome is not reported in the registry record. The event-specific timeframe is 12 weeks; further information about how incomplete follow-up or missing event assessments were handled is not reported in the registry record.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

What does a participant count measure?

The primary endpoint is a count of participants with treatment-related adverse events during 12 weeks. In general, a participant-level count answers how many people experienced at least one qualifying event; it is not the same as a count of every event. One participant may experience more than one event, so event totals and participant totals can differ. The registry record names the participant count as the primary measure, but does not report its numerical result.

The event definition in the record includes unfavorable events and clinically significant abnormal laboratory changes after etanercept administration, regardless of causal relationship. The sponsor evaluated causality separately. In general, keeping event occurrence distinct from attribution matters: observing an event after treatment does not by itself establish that treatment caused it. A causal judgment requires an explicit assessment process, and the details of that process beyond sponsor evaluation are not reported in the registry record.

How should event counts be interpreted?

Counts are descriptive. In general, they can show how many participants in a defined group experienced a recorded event, but they do not by themselves quantify a comparative effect or establish a cause. This distinction is especially important when the registry record does not describe a control group. Without a suitable comparison, the observed count cannot establish whether the event frequency is higher or lower than under another treatment strategy.

Small participant groups also make event counts unstable as estimates of broader experience. In general, when the group is small, each participant contributes substantially to the observed count, and uncertainty about the population frequency is correspondingly wide. A confidence interval can express a range of values compatible with the data under a statistical model. No confidence interval for the primary endpoint is reported in the registry record, so its precision cannot be assessed from that outcome.

What can a confidence interval say?

In general, a confidence interval communicates statistical uncertainty around an estimate and depends on the chosen method and assumptions. It does not correct for design limitations, missing outcomes, or biased selection into a study. It also does not establish clinical importance by itself. For this investigation, neither a primary endpoint estimate nor an interval is reported in the registry record, so no interval-based interpretation is available.

The serious-event listing reports a participant count, and the registry record also lists a percentage for Pneumonia. Those are descriptive safety details, not a substitute for an interval around the primary endpoint. The record does not report an interval or a detailed event-analysis method for these safety figures.

What does the sample-size planning description mean?

The registry record describes planning illustrations based on the observed effect, using a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation. The described illustrations consider detecting a stated fraction of the observed effect. In general, such calculations explore how many participants per arm would be needed under specified assumptions. They are planning illustrations, not observed power and not evidence that the study was designed or conducted with those sample sizes.

The record does not report a sample-size justification for the investigation itself. The numerical planning estimates are not reported in the registry record. Further, the described illustration assumes two-arm equal allocation, while the study description does not report a randomized comparison and does not identify a like-for-like control. These assumptions should not be mistaken for the actual study design or interpreted as a valid estimate of the investigation's ability to detect a treatment effect.

In general, over-dispersion occurs when observed variation exceeds what a model assumes. It can make standard errors too small and confidence intervals too narrow if ignored. No over-dispersion assessment or count-model specification is reported in the registry record. Given that the primary outcome is a participant count and the numerical result is absent, no such model-based interpretation can be made from the record.

What does the absence of listed analyses imply?

The registry record lists 0 analyses. This means analyses are not listed in the record; it does not establish that no analysis was performed elsewhere. The statistical analysis plan, any adjustment methods, the approach to confidence intervals, and any interim analyses are not reported in the registry record. Without those details, it is not possible to assess whether reported analyses followed a prespecified plan or how alternative analyses might affect interpretation.

In general, statistical significance tests address compatibility between data and a specified null hypothesis under model assumptions. A p-value does not measure the probability that a treatment works, and it does not communicate the size or practical importance of an effect. No test result or p-value for the primary outcome is reported in the registry record, so significance should not be inferred from the adverse-event counts or from the sample-size planning description.

10. Exact Estimates for Each Arm

No two-arm comparison is shown for this trial, but each arm's result can still be summarized with exact interval estimates computed from the posted counts. The Clopper-Pearson interval is exact and conservative; the Wilson interval is a common closer-to-nominal alternative; the Bayesian credible interval uses a uniform Beta(1, 1) prior. For small groups the three can differ noticeably.

R code and output

arm    <- c("Etanercept（Genetial Recombination）")
n      <- c(3)
events <- c(2)
for (i in seq_along(n)) {
  ci <- binom.test(events[i], n[i])$conf.int          # Clopper-Pearson exact interval
  cr <- qbeta(c(0.025, 0.975), 1 + events[i], 1 + n[i] - events[i])   # Bayesian, uniform Beta(1,1) prior
  wi <- (function(x, n) { p <- x / n; z <- qnorm(0.975); d <- 1 + z^2 / n
    c((p + z^2 / (2 * n) - z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d, (p + z^2 / (2 * n) + z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d) })(events[i], n[i])
  cat(sprintf("ARM|%s|%d|%d|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f\n", arm[i], n[i], events[i], 100 * events[i] / n[i],
              100 * ci[1], 100 * ci[2], 100 * wi[1], 100 * wi[2], 100 * cr[1], 100 * cr[2]))
}

ARM  Etanercept（Genetial Recombination）  3  2  66.7  9.4  99.2  20.8  93.9  19.4  93.2

11. Multiplicity, Missing Data and Analysis Populations

The registry record lists 5 outcome measures, including the primary endpoint of participants with treatment-related adverse events and a secondary outcome concerning physician assessment of clinical effect on symptoms and change in laboratory values. The remaining outcome measures and their results are not reported in the registry record. It lists 0 analyses, so no analysis results are listed in the record.

When several outcomes or statistical tests are examined, the chance of at least one apparently unusual result can increase. In general, multiplicity methods may address this by adjusting interpretation or analysis across outcomes, but such methods are not reported in the registry record. The record also does not describe a hierarchy for secondary outcomes or distinguish confirmatory from exploratory analyses.

Missing-data procedures are not reported in the registry record. The number of participants with complete primary endpoint follow-up, the handling of withdrawals or incomplete safety assessments, and any imputation or sensitivity analyses are not reported in the registry record. The enrollment is 3, but that number alone does not establish how many participants contributed to each outcome at each assessment.

The safety analysis population is defined as participants whose regimen changed from 10 mg twice weekly to 25 mg once weekly for rheumatoid arthritis. The registry record does not report further analysis-population definitions, such as separate efficacy or per-protocol populations. It also does not report whether the primary analysis included every enrolled participant or how deviations from the intended regimen were handled. These omissions limit assessment of the relationship between the defined population, the posted adverse-event figures, and the unreported primary endpoint result.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: pneumonia (33.3%).

The registry record lists 1 participant with a serious adverse event and 2 participants with other adverse events in the etanercept group. It also identifies Pneumonia with a listed value of 33.3% among the top serious-event terms. These are descriptive safety figures. The record does not provide enough detail to determine whether the serious event and other events occurred in different participants or whether any participant contributed to more than one category.

The serious-event listing should not be treated as the primary endpoint result. The primary endpoint counts participants with treatment-related adverse events, while the broad adverse-event definition includes events regardless of causal relationship. The registry record says the sponsor evaluated causality, but the causal classifications associated with the listed safety counts are not reported in the registry record.

The percentage associated with Pneumonia does not establish the event's relationship to etanercept, its severity beyond its placement in the serious-event listing, or its frequency in a broader population. The registry record does not report a detailed denominator or participant-level account for this term. Deaths are not reported in the registry record.

In general, serious adverse-event counts are descriptive observations within the recorded study group. They do not establish a comparative risk without an appropriate comparison, and they do not show that treatment caused an event. Here, the record does not describe a like-for-like control comparison, and enrollment was 3. The figures should therefore be read narrowly as the listed observations from this investigation.

13. What the Result Does, and Does Not, Mean

The record establishes that a completed post-marketing investigation enrolled 3 participants with rheumatoid arthritis who changed their etanercept regimen from 10 mg twice weekly to 25 mg once weekly. It defines a primary safety endpoint covering 12 weeks and lists safety observations, including 1 participant with a serious adverse event, 2 with other adverse events, and Pneumonia at 33.3% among the top serious-event terms.

Those details do not establish the result for the primary endpoint. The primary endpoint is specifically the number of participants with treatment-related adverse events, but that result is not reported in the registry record. The broad adverse-event counts cannot be substituted for it because the broad definition includes events regardless of cause, while the primary endpoint is limited to events considered treatment-related. The record does not provide the information needed to reconcile those categories.

The findings also do not establish that etanercept caused or prevented an adverse event, or that changing the regimen improved or worsened rheumatoid arthritis symptoms. No control comparison is described, and the named secondary outcome has no reported result. The post-marketing setting and the specified group of patients also limit how readily the observations can be generalized to people outside that group.

In general, an observed count is evidence about what was recorded among the participants studied, not a guarantee of what would occur in a larger or different population. The small enrollment makes precision particularly difficult to assess, and no confidence interval or analysis result is reported in the registry record. No treatment recommendation follows from these registry entries. The record supports a description of the study and its listed safety figures, while leaving the primary endpoint result, comparative effect, and uncertainty unreported.

14. Why This Trial Matters Statistically

Small post-marketing investigations can document how safety outcomes are recorded in a defined group after a treatment regimen changes. This investigation makes the population and regimen of interest explicit: patients with rheumatoid arthritis and inadequate response to prior conventional therapy who changed from etanercept 10 mg twice a week to 25 mg once a week. It also specifies a 12-week primary safety timeframe and defines adverse events broadly.

Statistically, the record illustrates why outcome definitions and causal attribution must be kept distinct. The broad event definition includes unfavorable events regardless of causality, while the primary endpoint concerns events considered treatment-related. The sponsor assessed causality, but the primary endpoint result and detailed causal classifications are not reported in the registry record. Without those results, the listed serious and other adverse-event counts cannot answer the primary question.

The enrollment of 3 also highlights the limits of descriptive safety counts. In general, counts in small groups can be useful for documenting observed events, but they provide little basis for precise estimates of event frequency or comparisons with other groups. The registry record does not report an interval estimate or a control comparison, so the uncertainty and relative interpretation remain unresolved.

The record lists a secondary clinical-effect outcome but no result for it, and lists 0 analyses. This makes clear that registered outcome definitions and an investigation's stated purpose are not the same as available evidence about an outcome. For statistical interpretation, transparent reporting of numerical results, analysis populations, missing-data handling, and uncertainty is essential. Those details are not reported in the registry record. The study therefore matters as a case in separating a clearly described safety question from the inferential conclusions the posted information can support.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The main limitation is that the primary endpoint result is not reported in the registry record. The record defines the number of participants with treatment-related adverse events over 12 weeks, but does not provide the count or an uncertainty estimate. The posted serious and other adverse-event figures do not replace that endpoint because the broad event definition includes events regardless of causality.

Enrollment was 3, which sharply limits the amount of information available for describing event patterns beyond the participants studied. The record does not report confidence intervals for the primary outcome or the listed safety observations. It also does not provide participant-level information showing overlap between serious and other events, or the causal classification for each event.

A control group, randomization procedure, and allocation method are not reported in the registry record. The record states that allocation is not stated and that arms are not a like-for-like control comparison. Consequently, the observations cannot establish a comparative effect. The secondary outcome is named, but its results are not reported in the registry record.

Further limitations include the absence of reported details on missing data, follow-up completion, outcome-assessment procedures, and the statistical analysis plan. The registry record does not report a sample-size justification, interim analyses, multiplicity handling, or sensitivity analyses. It lists 0 analyses, which means no analyses are listed in the record; it does not show whether analyses were performed elsewhere. These reporting gaps limit evaluation of both precision and robustness.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Etanercept (Enbrel) Special Investigation (Regulatory Post Marketing Commitment Plan) — NCT01230177.
• Registry record last updated 2017-02-23; status last verified 2017-01.
• Results first posted 2017-02-23.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

NCT01230177 is a completed post-marketing special investigation of etanercept in patients with rheumatoid arthritis who had an inadequate response to prior conventional therapy and changed from 10 mg twice weekly to 25 mg once weekly. Enrollment was 3. The study start is recorded as 2011-05, and primary completion as 2013-04.

The primary endpoint is the number of participants with treatment-related adverse events during 12 weeks. Its result is not reported in the registry record. The safety listing includes 1 participant with a serious adverse event, 2 with other adverse events, and Pneumonia at 33.3% among the top serious-event terms. The registry record also names a secondary outcome concerning physician assessment of clinical effect and laboratory-value changes, but does not report its result. A control comparison, analysis results, missing-data procedures, and statistical plan are not reported in the registry record.